Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,782,994
  • Shares Outstanding, K 515,437
  • Annual Sales, $ 11,434 M
  • Annual Income, $ 352,500 K
  • 60-Month Beta 1.44
  • Price/Sales 0.86
  • Price/Cash Flow 2.21
  • Price/Book 0.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.97
  • Number of Estimates 7
  • High Estimate 1.08
  • Low Estimate 0.88
  • Prior Year 1.07
  • Growth Rate Est. (year over year) -9.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.92 +0.29%
on 05/24/19
28.45 -33.30%
on 05/06/19
-7.46 (-28.21%)
since 04/24/19
3-Month
18.92 +0.29%
on 05/24/19
31.75 -40.22%
on 02/25/19
-12.28 (-39.28%)
since 02/22/19
52-Week
18.92 +0.29%
on 05/24/19
42.50 -55.34%
on 06/13/18
-20.35 (-51.74%)
since 05/24/18

Most Recent Stories

More News
Amgen (AMGN) Offers to Acquire Drug Discovery Platform

Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

MYL : 18.98 (-0.99%)
LLY : 116.79 (-0.02%)
CHRS : 20.36 (unch)
AMGN : 171.28 (-0.48%)
Shares of MYL Down 28.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Mylan Nv (NASDAQ:MYL) on February 27th, 2019 at $27.53. In approximately 3 months, Mylan Nv has returned 28.15% as of today's recent price of $19.78.

MYL : 18.98 (-0.99%)
After Yesterday's Decline of 1.83%, Mylan Nv Offers Investors Better Value

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $19.26 to a high of $19.30. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $19.40 on...

MYL : 18.98 (-0.99%)
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week...

TBPH : 18.18 (-0.44%)
MYL : 18.98 (-0.99%)
Watch for Shares of Mylan Nv (MYL) to Approach Support at $19.18

Shares of Mylan Nv (NASDAQ:MYL) have bearishly opened below the pivot of $19.90 today and have reached the first support level of $19.42. Should the shares continue to fall, the support pivots of $19.18...

MYL : 18.98 (-0.99%)
Mylan Presents Equivalence and Device Usability Data on Wixela(TM) Inhub(TM) Compared to Advair Diskus® at American Thoracic Society International Conference

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced four scientific abstracts from the Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP) development...

MYL : 18.98 (-0.99%)
Mylan to Host Investor Day on July 31, 2019 in New York City

Mylan N.V. (NASDAQ: MYL) yesterday presented at the Bank of America Merrill Lynch Healthcare Conference, where the company announced that it will host an Investor Day on July 31, 2019 in New York City....

MYL : 18.98 (-0.99%)
Mylan and Biocon to Present Final Overall Survival Data for Ogivri(TM) (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that final data from the HERITAGE study will be presented at the 2019 American Society of Clinical Oncology (ASCO)...

MYL : 18.98 (-0.99%)
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

MYL : 18.98 (-0.99%)
NVS : 87.52 (+3.65%)
TEVA : 10.87 (-1.54%)
PFE : 41.95 (+0.07%)
AbbVie Settles Humira Litigation With Boehringer Ingelheim

AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

MYL : 18.98 (-0.99%)
ABBV : 80.06 (-1.34%)
AMGN : 171.28 (-0.48%)
PFE : 41.95 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MYL with:

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 19.68
1st Resistance Point 19.33
Last Price 18.98
1st Support Level 18.78
2nd Support Level 18.57

See More

52-Week High 42.50
Fibonacci 61.8% 33.49
Fibonacci 50% 30.71
Fibonacci 38.2% 27.93
Last Price 18.98
52-Week Low 18.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar